JPH10265390A - Composition for inhibiting abdominal disorder - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition capable of relaxing or depressing abdominal disorders such as abdominal pain and diarrhea caused by the intake of lactose by including a specific ingredient. SOLUTION: This composition contains lactosucrose as an active ingredient. Therein, the lactosucrose is preferably contained in an amount of about 0.0001-1 g per g of the composition. When lactose is contained together with the lactosucrose, the lactosucrose and the lactose are preferably contained in a solid content ratio of 0.01:1 to 1:0.01. The lactosucrose is orally or enterally administered at a daily dose of about 0.1-50 g once to four times per day or once to ten times per week.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to a composition for suppressing abdominal abnormalities caused by lactose intake, and more particularly to a composition for suppressing abdominal abnormalities caused by lactose intake, which contains lactosucrose as an active ingredient. (Hereinafter, it may be simply referred to as “abdominal abnormality suppressing composition”).

[0002]

2. Description of the Related Art Lactosucrose is a trisaccharide consisting of galactose, glucose and fructose,
Its chemical structure is O-β-D-Gal- (1 → 4) -O
-Α-D-Glc- (1 ← 2) -β-D-Fru (however, Gal indicates a galactose residue, Glc indicates a glucose residue, and Fru indicates a fructose residue). Lactosucrose, as described in JP-B-59-53835, is a carbohydrate that has also attracted attention as a selective sugar source for bifidobacteria.

[0003] Conventionally, ingesting foods such as milk and dairy products while being healthy, to varying degrees, diarrhea,
Some people complain of various abdominal abnormalities, such as vomiting, nausea, wheezing, abdominal pain, bloating, flatulence or nausea. Such abdominal abnormalities are caused by lactose contained in food. It is known that such abdominal abnormalities caused by lactose intake are caused by a deficiency of congenital lactose-degrading enzyme or a secondary decrease in lactose-degrading enzyme activity. That is, congenital lactose-degrading enzyme deficiency may lead to more severe diarrhea, abdominal pain, and abdominal distension soon after birth, resulting in poor weight gain, growth disorders, and the like. In addition, although there is no lactose-degrading enzyme deficiency, abnormalities in excreting a large amount of milk diabetes due to enhanced membrane permeability of lactose in the intestinal tract, acute or chronic gastroenteritis, especially rotavirus enteritis, intractable diarrhea Due to illness, immunodeficiency, ulcerative colitis, Crohn's disease, gastrectomy, short bowel syndrome, antibiotic administration, etc., the lactose degrading enzyme in the intestinal tract decreases secondarily,
Abnormalities such as diarrhea, abdominal pain, abdominal distension, poor weight gain, and stunting may also be present.

[0004] Lactose-deficient enzyme-deficient persons are refrained from ingesting lactose-containing foods and are administered lactose-degrading enzymes. However, in order to prevent unpleasant abdominal abnormalities caused by lactose-containing foods, it is necessary to avoid conscious consumption of such foods, which not only involves mental distress but also However, the types of foods that can be eaten and eaten are limited, and there is a problem in terms of nutritional balance. In addition, administration of lactose-degrading enzyme is not always satisfactory in terms of handleability, safety, and effects.

[0005] Under such circumstances, there is a need for establishment of a composition for suppressing abdominal abnormalities which can alleviate or suppress abdominal abnormalities caused by lactose intake.

[0006]

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for suppressing abdominal abnormalities which can alleviate or suppress abdominal abnormalities caused by lactose intake.

[0007]

Means for Solving the Problems The present inventors have intensively studied the use of lactosucrose. as a result,
Lactosucrose has been found to have the effect of significantly reducing or suppressing abdominal abnormalities caused by lactose intake,
The present invention was completed by establishing a composition for suppressing abdominal abnormalities caused by lactose ingestion using this lactosucrose as an active ingredient. That is, the present invention solves the above-mentioned problems by providing a composition for suppressing abdominal abnormalities caused by lactose intake, which contains lactose sucrose as an active ingredient.

[0008]

The composition for suppressing abdominal abnormalities caused by lactose intake comprising lactose sucrose as an active ingredient according to the present invention is a lactose-containing food, that is, a specific product caused by lactose intake due to the action of lactose sucrose as an active ingredient. Abdominal abnormalities such as abdominal pain, wheezing, bloating, diarrhea, vomiting, nausea,
It effectively alleviates or suppresses abnormalities in the digestive tract such as the stomach, small intestine, and large intestine. In addition, the person complaining of the abdominal abnormality when ingesting lactose-containing food, by daily ingesting the composition for suppressing abdominal abnormality of the present invention, even when ingesting lactose-containing food, the abdominal abnormality is significantly reduced or While being suppressed, by adding and eating a predetermined amount of the composition for suppressing abdominal abnormalities of the present invention to lactose-containing foods,
The abdominal abnormality can be effectively alleviated or suppressed.

[0009]

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, embodiments of the present invention will be described. Lactosucrose used in the present invention comprises:
Any of natural products, including commercially available products, or products synthesized enzymatically or chemically can be used. Specifically, a material having a relatively low purity of less than 10% and a material having a high purity of 99% or more can be used. The purity of lactosucrose to be used may be appropriately selected depending on the final form of the composition for suppressing abdominal abnormalities of the present invention.

[0010] The method for producing lactosucrose used in the present invention can be, for example, a method of reacting an aqueous solution containing sucrose and lactose with a glycosyltransferase such as fructosetransferase or galactosetransferase. Examples of fructose transferase include, for example, JP-B-57-58905 and JP-B-59-5383.
No. 5 Bacillus (Bacillu)
s) Levansucrase derived from a microorganism belonging to the genus or the genus Aerobacter or a microorganism belonging to the genus Arthrobacter, for example, Arthrobacter sp. described in JP-A-3-27285. Arthrobacterte
r sp. ) Β-fructofuranosidase derived from K-1 (FERM BP-3192) is advantageously used,
Examples of galactose transferase include Canadian Journal of Chemistry (Canad).
ian Journal of Chemistr
y), Vol. 43, pp. 2259-2264 (1965)
) And Japanese Patent Application No. 64-85090.
es) Enzymes derived from microorganisms belonging to the genus and the microorganisms belonging to the genus Rahnella described in Japanese Patent Application No. 2-35095 are advantageously used, and cells of these microorganisms or extracts thereof are advantageously used. Used for As a method for obtaining lactosucrose having relatively high purity, for example, as disclosed in Japanese Patent Application No. 4-281595, column chromatography using an alkali metal or alkaline earth metal type strongly acidic cation exchange resin is used. There is a way. As the cation exchange resin,
One or more of alkali metal types such as Na ⁺ type and K ⁺ type or alkaline earth metal types such as Mg ⁺⁺ type and Ca ⁺⁺ type of a styrene-divinylbenzene cross-linked copolymer having a sulfone group bonded thereto Is appropriately used. As a commercial product,
For example, Dowex 50W manufactured by Dow Chemical Company
X1, Dowex 50WX2, Dowex 50WX
450, trade names Amberlite CG-120, Amberlite CG-600 manufactured by Rohm and Haas
0, Amberlite XT-1022E and Amberlite XT-100 manufactured by Tokyo Organic Chemical Industry Co., Ltd.
7. Diaion S manufactured by Mitsubishi Kasei Kogyo Co., Ltd.
K1B, Diaion SK102, Diaion SK1
04. In addition to these cation exchange resins, anion exchange resins can be used as appropriate. When the highest purity lactosucrose is required, the purity can be adjusted by appropriately combining salting out, dialysis, filtration, concentration, fractionated precipitation, crystallization, gel filtration chromatography, ion exchange chromatography, high performance liquid chromatography, etc. 99% or more of lactosucrose can be obtained.
In addition, lactosucrose having a purity of about 30 to 80% is preferable from the viewpoint of production cost.

The lactosucrose content of the composition for suppressing abdominal abnormalities of the present invention is usually about 0.0001 to 1 g, preferably about 0.1 to 1 g per gram of the composition.
g, more preferably about 0.7-1 g, even more preferably about 0.75-1 g. The daily adult intake is about 0.1-50% by weight of lactosucrose solids.
g, desirably 1 to 25 g 1 to 4 times / day or 1
Administered orally or gavage at a rate of ~ 10 times / week.

When the composition for suppressing abdominal abnormality of the present invention contains lactose and lactose, the proportion of lactose and lactose (the proportion of lactose and lactose) is 0.01% by weight of solids. : 1 to 1: 0.0
1, preferably from 0.1: 1 to 1: 0.1, more preferably from 0.2: 1 to 1: 0.2. The components other than lactosucrose contained in the composition for suppressing abdominal abnormalities of the present invention are not particularly limited as long as they are edible components. Preferred examples include hydrophilic organic solvents such as water and alcohol, glucose, monosaccharides such as fructose, maltose, sucrose, disaccharides such as α, α-, α, β- and β, β-trehalose, dextrin,
α-, β- and γ-cyclodextrin, starch syrup, non-reducing carbohydrate having a trehalose structure at the terminal or in the molecule, isomerized sugar, oligosaccharide or polysaccharide such as starch, xylitol, erythritol, maple sugar, sorbitol, Natural and synthetic sweeteners such as maltitol, lactitol, dihydrochalcone, stevioside, α-glycosylstevioside, rebaudioside, glycyrrhizin, α-glycosylglycyrrhizin, L-aspartyl-L-phenylalanine methyl ester, saccharin, glycine, alanine and honey, calcium Minerals such as magnesium, phosphorus or salts thereof, L-ascorbic acid, α-glycosylascorbic acid, rutin,
Components such as α-glycosyl rutin, hesperidin, α-glycosyl hesperidin, quercetin, α-glycosyl quercetin and the like can be mentioned. These components other than lactosucrose are used alone or in an appropriate combination of two or more, and are used in an amount of about 0.01 to 99 w / w%, preferably about 0.1 to 80 w / w% based on the weight of the lactosucrose solid.
The w / w%, more preferably, about 1 to 60 w / w%, further preferably, about 5 to 50 w / w% is blended. In addition, an appropriate amount of a flavor, a coloring agent, a taste improver, or the like may be appropriately added.

When the composition for suppressing abdominal abnormalities of the present invention is used as a medicine, not only lactosucrose as an active ingredient but also all ingredients to be used must be of pharmaceutically acceptable quality.

When the composition for suppressing abdominal abnormalities of the present invention is a liquid preparation or a semisolid preparation, it is used as a stabilizer for lactosucrose, especially as a pH buffer, in order to keep lactosucrose stable during storage. One or more kinds of organic acids such as citric acid, tartaric acid, lactic acid, fumaric acid, malic acid, carbonic acid and salts thereof can be used as appropriate. Salts of these organic acids include sodium citrate, sodium tartrate, sodium malate, calcium lactate, sodium lactate, sodium hydrogen phosphate, sodium carbonate,
Examples thereof include sodium hydrogen carbonate. Using one or more of the above pH buffers, pH 4 to 8.5, preferably pH 5 to 8, more preferably pH 6.6 to
By adjusting the composition for suppressing abdominal abnormality of the present invention within the range of 7.5, lactosucrose can be stably maintained.

The method for incorporating lactosucrose is as follows.
It may be included in the process until the composition for suppressing abdominal abnormalities of the present invention is completed. For example, known methods such as mixing, dissolving, melting, dipping, penetrating, spraying, coating, coating, spraying, injecting and solidifying. Can be used as appropriate. Further, the composition for suppressing abdominal abnormalities of the present invention, in the manufacturing process or the final step,
Sterilize by membrane filtration, heat sterilization, pressure sterilization, chemical sterilization, etc.

Hereinafter, the present invention will be specifically described by experiments.

[0017]

[Experiment 1] Subject 1 complaining of strong abdominal abnormalities after ingesting milk
For one person (one man and ten women aged 19-21)
The following lactose tolerance test was performed. That is, an aqueous solution obtained by dissolving 20 g of lactose having a purity of about 99.5% in 200 ml of sterilized distilled water and sterilizing by membrane filtration is orally administered to a subject, and thereafter, blood is collected every 60 minutes for 240 minutes. Exhaled air was collected, and the blood glucose level, the exhaled hydrogen gas concentration, and the methane gas concentration were measured. In addition, the subjects were also examined for symptoms when exhaled air was collected.

In addition, subjects who have performed the lactose tolerance test
5 g of lactosucrose having a purity of about 99% was dissolved in 50 ml of sterilized distilled water, and an aqueous solution sterilized by membrane filtration was orally ingested once a day at lunch time for one week (hereinafter simply referred to as "lactosucrose"). "Sucrose intake".) Thereafter, these subjects were again subjected to the lactose tolerance test.

Based on these experimental results, the time-dependent changes in the exhaled hydrogen gas concentration (average value of 11 subjects) and the exhaled methane gas concentration (average value of 11 subjects) in a lactose tolerance test before and after ingestion of lactosucrose are shown. 1 and FIG. In FIGS. 1 and 2, p <0.01 and p
<0.05 indicates significant at the significance level of 1% and 5%, respectively.

As is clear from FIG. 1, in the lactose tolerance test after ingestion of lactose, the hydrogen gas concentration in the breath showed a low value for 60 to 240 minutes after lactose challenge. In particular, the hydrogen gas concentration in the breath after lactose loading showed a significant difference due to lactose sucrose intake 120 minutes and 240 minutes after lactose loading. Further, as is apparent from FIG. 2, in the lactose tolerance test after ingestion of lactosucrose, the methane gas concentration in the exhaled breath was changed after lactose loading.
After 120 minutes, the value was significantly lower than before the ingestion of lactose.

Table 1 shows the measured values of the maximum exhaled hydrogen gas concentration in the lactose tolerance test performed before and after the intake of lactose, and the maximum exhaled gas after the lactose tolerance test before and after the intake of lactose. FIG. 3 shows changes in the concentration of the middle hydrogen gas. In FIG. 3, p <0.05
Indicates that significance is significant at the significance level of 5%.

[0022]

[Table 1]

As shown in Table 1, the maximum exhaled hydrogen gas concentration in the lactose tolerance test performed before ingestion of lactosucrose was 27.20 ± 4.88 (mean ± standard error) p.
pm, whereas the maximum exhaled hydrogen gas concentration in a lactose tolerance test performed after lactosucrose ingestion was 14.
36 ± 2.87 (mean ± standard error) ppm, which was significantly lower than that before ingestion of lactosucrose.

FIGS. 4, 5, 6, and 7 show the results of averaging the results of the survey on the symptoms of the subject.

In FIGS. 4 to 7, the numerical values on the vertical axis are as follows.
Regarding the degree of each symptom of "abdominal pain", "stomach belly", "abdominal bloating" and "nausea", "no symptom (0 point)"
"Slight symptoms (1 point)", "Symptoms (2 points)
), "Symptoms are somewhat strong (3 points)", "Symptoms are strong (4 points)", and "Symptoms are remarkably strong (5 points)". Number of subjects (1
1). As is clear from FIGS. 4 to 7, it was found that lactose sucrose intake significantly alleviated abdominal pain, wheezing, abdominal distension and nausea due to lactose load. In addition, although data are not shown, the blood glucose level of the subject after lactose load did not change depending on the presence or absence of lactosucrose ingestion. From these results, it was found that lactosucrose can effectively alleviate or suppress the specific abdominal abnormality caused by lactose intake.

[0026]

[Experiment 2] <Acute toxicity test> High-purity lactosucrose having a purity of about 90% prepared according to Reference Example 2 described below was added to a 7-week-old dd.
When an acute toxicity test was performed by oral administration to a strain mouse, no death was observed up to 6 g per 1 kg of mouse body weight, and further administration was difficult. Thus, the toxicity of lactose is extremely low.

The following is a typical preparation example of lactosucrose used in the present invention.

[0028]

Reference Example 1 <Preparation of Lactosucrose> 3 parts by weight of sucrose and 3 parts by weight of lactose were dissolved by heating in 10 parts by weight of water, and then
After cooling to 0 ° C., levansucrase was added thereto at a ratio of 1.5 units per sucrose, and the mixture was added at 40 ° C., pH 6.0.
And kept for 16 hours. The enzyme was then inactivated by heating, filtered, and the filtrate was decolorized with activated carbon according to a conventional method.
Then, the mixture was desalted with H-type and OH-type ion exchange resins and concentrated to obtain a sugar solution having a concentration of about 50 w / w%. This sugar solution is
The sugar composition contained about 30% w / w lactosucrose.

The resin used for the fractionation was an alkali metal type strongly acidic cation exchange resin (manufactured by Dow Chemical Company, trade name: Dowex 50WX4, K ⁺ type, degree of cross-linking 4%), and a jacketed stainless steel having an inner diameter of 5.4 cm. The column was filled with an aqueous suspension, and four columns were connected so that the liquid flowed in series, so that the total length of the resin layer was 8 m. Column temperature 6
While maintaining 0 ° C., the raw sugar liquid is added to
Then, hot water at 60 ° C. was flowed at an SV of about 0.3 to fractionate the solution, and a solution containing about 50 w / w% of lactosucrose in sugar composition was obtained. ,
Concentration and spray drying gave a lactosucrose powder with a water content of less than 2% w / w in a yield of about 50%.

[0030]

Reference Example 2 <Preparation of Lactosucrose> A sugar solution containing about 40% w / w% of lactosucrose obtained according to the method of Reference Example 1 was used as a fractionation resin as an alkaline earth metal type strongly acidic cation exchange resin ( Manufactured by Mitsubishi Chemical Industry Co., Ltd.
K104, Ca ⁺⁺ type, degree of crosslinking 4%)
Fractionation was performed in the same manner as in Reference Example 1 to obtain an aqueous solution containing about 85 w / w% of lactosucrose in sugar composition, which was decolorized, desalted, concentrated, spray-dried, and dried to a water content of less than 2 w / w%. Was obtained in a yield of about 30%.

[0031]

[Reference Example 3] <Preparation of Lactosucrose>

Reference Example 3- (1) Arthrobacter sp. K on a normal agar slant medium
-1 (FERM PB-3192), incubate at 37 ° C. for 2 days, take one platinum loop, and extract yeast extract.
2 w / v%, polypeptone 0.8 w / v%, soluble starch 4 w / v%, (NH ₄ ) ₂ HPO ₄ 0.4 w / v%, M
_{gSO 4 · 7H 2 O 0.1w /} v%, liquid medium consisting of tap water (pH 7.0) to a 500ml-volume shaking flask 6
0 ml each, inoculated into sterilized one, and
Shaking culture was performed for a day. After completion of the culture, the culture is centrifuged,
About 1.1 L of a supernatant containing β-fructofuranosidase was obtained. This enzyme solution showed a β-fructofuranosidase activity of about 30 units / ml.

The method for measuring the activity of β-fructofuranosidase is as follows. 20% sucrose solution containing 40% xylose (500 mM phosphate buffer, pH 6.5) 20
Add 200 μl of the enzyme solution appropriately diluted to 0 μl, and add
After 10 minutes of action at 10 ° C., a part of the reaction solution was put into boiling water to inactivate the enzyme, and then the amount of glucose and fructose released was measured using an F-kit (a product sold by Boehringer Mannheim Yamanouchi Co., Ltd.). Name), and the amount of fructose transferred is calculated by subtracting the amount of fructose from the amount of glucose. One unit is defined as the amount of enzyme that transfers 1 μmole of fructose per minute.

[0033]

REFERENCE EXAMPLE 3- (2) 1 part by weight of sucrose and 1 part by weight of lactose were dissolved in 3 parts by weight of water under heating, cooled to 50 ° C., and adjusted by the method of Reference Example 3- (1). After adding β-fructofuranosidase at a ratio of 5 units per sucrose gram and reacting at 50 ° C. and pH 6.5 for 5 hours, the enzyme was inactivated, filtered, and the filtrate was decolorized and decolored according to a conventional method. It was salted and concentrated to obtain a sugar solution having a concentration of about 60 w / w%. This sugar solution contained about 30% w / w lactosucrose in sugar composition.

The sugar solution was fractionated in the same manner as in Reference Example 2 except that the used resin was changed to an alkaline earth metal type (Mg ⁺⁺ type) as a resin for fractionation, and the sugar composition was changed to lactosucrose. Was obtained, and further purified, concentrated and spray-dried in the same manner as in Reference Example 2 to obtain a lactosucrose powder having a water content of less than 2 w / w% in a yield of about 45%.

[0035]

REFERENCE EXAMPLE 4 <Preparation of Lactosucrose> An alkali metal-type strongly acidic cation exchange resin containing a sugar solution containing about 30% w / w% of lactosucrose obtained by the method of Reference Example 3 as a fractionation resin was used. (Manufactured by Rohm and Haas Co., trade name: Amberlite CG-6000, Na ⁺ type, degree of cross-linking: 6%). / W% containing aqueous solution,
Further purified and concentrated in the same manner as in Reference Example 2, spray-dried,
Lactose sucrose powder having a water content of less than 2 w / w% can be obtained in a yield of about 3
Obtained at 5%.

[0036]

Reference Example 5 <Preparation of Lactosucrose> 1 part by weight of sucrose and 1 part by weight of lactose were dissolved in 2 parts by weight of water, and then dissolved in 50 parts by weight.
C., and β-fructofuranosidase prepared by the method of Reference Example 3- (1) was added thereto at a rate of 8 per sucrose gram.
The reaction was carried out for 20 hours while maintaining the temperature at 50 ° C. and the pH at 6.0, and then the enzyme was deactivated by heating, followed by filtration to obtain a filtrate.

This solution contained about 35 w / w% lactosucrose in sugar composition, and monosaccharides such as glucose and fructose and oligosaccharides such as lactose and sucrose as contaminating saccharides.

This solution was adjusted to a sugar concentration of about 30 w / w%, and an invertase-deficient yeast (trade name “LS-Y”, manufactured by Oriental Yeast Co., Ltd., water content: about 65%) was added at 5 w / w per solid sugar. %, PH 6.5 to 7.0, temperature 3
The mixture was kept at 0 ° C. for 24 hours, and the monosaccharides contained in the sugar solution were fermented and digested to obtain a solution containing about 46% w / w of lactosucrose in the sugar composition. Then, the solution was decolorized and desalted according to a conventional method. , Concentrated and spray dried to give lactosucrose powder with less than 3% moisture in about 64% yield.

[0039]

Reference Example 6 <Preparation of Lactosucrose> A sugar solution containing about 50 w / w% of lactosucrose obtained according to the method of Reference Example 5,
Concentrate to a concentration of about 78% w / w, add a small amount of crystalline lactose as seed crystals at 50 ° C, slowly cool to 30 ° C and stir to crystallize lactose, then centrifuge and filter to remove crystalline lactose. To give a solution containing about 50% w / w of lactosucrose in sugar composition, and then decolorizing, desalting, further concentrating and spray-drying the lactosucrose having a water content of less than 3% according to a conventional method. The powder yield is about 66
%.

[0040]

REFERENCE EXAMPLE 7 <Preparation of Lactosucrose> 4 parts by weight of sucrose and 5 parts by weight of lactose were dissolved in 13.5 parts by weight of water under heating and then cooled to 55 ° C. The β-fructofuranosidase prepared by the method was added at a rate of 10 units per gram of sucrose, reacted at 55 ° C. and pH 6.5 for 15 hours, and then inactivated by heating the enzyme,
Filtration gave a filtrate.

This solution contained about 33 w / w% lactosucrose in sugar composition, and monosaccharides such as glucose and fructose and oligosaccharides such as lactose and sucrose as contaminating saccharides.

This liquid was concentrated to a solid concentration of about 78 w / w%, a small amount of crystalline lactose was added as a seed crystal, and lactose was crystallized while stirring at 50 ° C., and then filtered to remove crystalline lactose. The resulting filtrate is concentrated to a solid concentration of about 3
0 w / w%, and monosaccharides were fermented and digested with an invertase-deficient yeast in the same manner as in Reference Example 5 to obtain a solution containing about 50 w / w% of lactosucrose in a sugar composition. According to, decolorization, desalting,
Concentration and spray drying gave a lactosucrose powder with less than 2% moisture in about 52% yield.

[0043]

Example 1 <Tablets> 60 parts by weight of lactosucrose obtained in Reference Example 2,
After uniformly mixing 1 part by weight of tribasic calcium phosphate, 1 part by weight of sugar ester, 5 parts by weight of L-ascorbic acid and an appropriate amount of powdered flavor, the mixture is sterilized by heating at 80 ° C. for 1 hour. Then, the tablets were obtained by aseptic tableting using a tableting machine.

The product is an easy-to-drink tablet having good stability without cracking. When used, it may be chewed and swallowed. This product is usually about 1-3 adult per day
By taking 0 tablets, preferably about 5 to 20 tablets, it is possible to effectively reduce abdominal abnormalities caused by lactose intake such as abdominal pain, wheezing, abdominal bloating, diarrhea, vomiting, and nausea caused by ingesting dairy products. Can be alleviated or suppressed. Lactosucrose, the active ingredient of this product,
Bifidobacterium growth promotion, also has calcium absorption promotion, beauty, maintenance and promotion of health, prevention of adult diseases such as osteoporosis, treatment and prevention of various diseases, further,
It can also be used advantageously to maintain and recover health. In addition, this product
It also has the effect of inhibiting the production of intestinal putrefaction products.

[0045]

Example 2 <Tube nutrition> 580 parts by weight of the high lactosucrose content obtained in Reference Example 2, 4.4 parts by weight of sodium chloride, 1.85 parts by weight of potassium chloride, 4 parts by weight of magnesium sulfate, 0 parts of thiamine .01 parts by weight, sodium ascorbate 0.1.
A composition consisting of 1 part by weight, 0.6 part by weight of vitamin E acetate and 0.04 part by weight of nicotinamide was heated at 85 ° C.
After heat sterilization for 1 hour, 10 g each of the composition was filled in a laminated aluminum pouch and heat-sealed to produce a composition for suppressing abdominal abnormalities.

The product is stable in quality for a long time, and has good solubility and dispersibility. For use, one bag of this product is dissolved in about 100 to 300 ml of purified water and taken orally, or administered to the nasal cavity, esophagus, stomach, etc. by tube administration. The product can effectively alleviate or suppress abdominal abnormalities caused by lactose intake such as abdominal pain, belly stomach, abdominal bloating, diarrhea, vomiting, and nausea caused by ingesting dairy products. In addition, this product also has a bifidobacterium growth promotion effect and calcium absorption promotion effect, beauty, maintenance and promotion of health, prevention of adult diseases, treatment of various diseases,
It can be advantageously used for prevention and also for maintenance and recovery of health.

[0047]

Example 3 <Solution> 10 parts by weight of lactosucrose obtained in Reference Example 1,
1 part by weight of L-ascorbic acid, 1 part by weight of trehalose,
After 5 parts by weight of purified water and an appropriate amount of powdered flavor are mixed uniformly, the mixture is adjusted to pH 7.2 with a pH adjuster, sterilized by membrane filtration, and then 100 ml in a sterilized plastic container.
Each was filled.

The product can be taken alone, or when eating and drinking dairy products such as milk, yogurt, etc.
By adding and drinking about 10 to 30 ml of this product, it is possible to effectively alleviate abdominal abnormalities caused by lactose intake such as abdominal pain, bellows, abdominal bloating, diarrhea, vomiting, and nausea caused by ingesting dairy products Alternatively, it can be suppressed.

[0049]

Embodiment 4 <Solution> 6 parts by weight of sodium chloride, 0.3 of potassium chloride
Parts by weight, 0.2 parts by weight of calcium chloride, 3 parts by weight of sodium lactate, 45 parts by weight of maltose, and 500 parts by weight of lactose sucrose obtained in Reference Example 3 were dissolved in 500 parts by weight of purified water, and pH 7. 0, and sterilized by membrane filtration.
ml.

The product can be taken alone, or when eating and drinking dairy products such as milk and yogurt,
By adding and drinking about 10 to 30 ml of this product, it is possible to effectively alleviate abdominal abnormalities caused by lactose intake such as abdominal pain, bellows, abdominal bloating, diarrhea, vomiting, and nausea caused by ingesting dairy products Alternatively, it can be suppressed.

[0051]

Example 5 <Solution> 2 parts by weight of calcium chloride, 20 parts by weight of trehalose, 2 parts by weight of α-glycosyl-L-ascorbic acid,
500 parts by weight of the lactosucrose powder obtained in Reference Example 6 was
Dissolve in 200 parts by weight of purified water, and adjust the pH with a pH adjuster.
It was adjusted to 7.5, sterilized by membrane filtration, and then filled into sterilized plastic containers in 200 ml increments.

The product can be taken alone, or when eating and drinking dairy products such as milk and yogurt,
By eating and drinking about 10 to 30 ml of this product, abdominal pain, wheezing caused when these dairy products are ingested,
Abdominal abnormalities caused by lactose intake such as abdominal bloating, diarrhea, vomiting, and nausea can be effectively alleviated or suppressed.

[0053]

Example 6 <Solution> Lactosucrose powder obtained in Reference Example 4
0 parts by weight, lactose 500 parts by weight, L-ascorbic acid 100 parts by weight, calcium lactate 50 parts by weight, and an appropriate amount of flavor and flavor are dissolved in purified water 1,500 parts by weight and adjusted to pH 7 with a pH adjuster. After being prepared, sterilized by membrane filtration, 500m in a sterilized plastic container
Each l was filled.

This product can be taken alone or by adding about 5 to 20 ml to a food and taking it daily, resulting in abdominal pain, wheezing, abdominal bloating, diarrhea caused by ingestion of dairy products. Abdominal abnormalities caused by lactose intake such as vomiting and nausea can be effectively alleviated or suppressed. The product can also be suitably used as a calcium reinforcing agent.

[0055]

As is clear from the above, the composition for suppressing abdominal abnormalities caused by lactose intake comprising lactose sucrose as an active ingredient of the present invention is characterized by abdominal pain, wheezing caused by lactose intake,
Abdominal abnormalities such as abdominal bloating, diarrhea, vomiting, and nausea can be effectively alleviated or suppressed. Further, by taking the abdominal abnormality suppressing composition of the present invention on a daily basis,
Abdominal abnormalities caused by ingestion of lactose-containing food can be alleviated or suppressed more effectively.

Further, the composition for suppressing abdominal abnormality of the present invention comprises:
Bifidobacterium growth promoting action, calcium absorption promoting action,
It also has an inhibitory effect on the production of intestinal putrefaction products, so it is advantageously used for maintaining and improving beauty and health, preventing adult diseases such as osteoporosis, treating and preventing various diseases, and further maintaining and recovering health. it can. As described above, the significance of the composition for suppressing abdominal abnormalities of the present invention is extremely large.

[Brief description of the drawings]

BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a graph showing a time-dependent change in a breathing hydrogen gas concentration in a lactose tolerance test before and after ingestion of lactosucrose.

FIG. 2 is a diagram showing the time-dependent changes in the methane gas concentration in breath in a lactose tolerance test before and after ingestion of lactosucrose.

FIG. 3 is a graph showing changes in the maximum exhaled hydrogen gas concentration in a lactose tolerance test before and after ingestion of lactosucrose.

FIG. 4 is a graph showing the time course of abdominal pain in a lactose tolerance test before and after ingestion of lactosucrose.

FIG. 5 is a graph showing the time course of the degree of wheezing in a lactose tolerance test before and after ingestion of lactosucrose.

FIG. 6 is a graph showing changes over time in the degree of abdominal distension in a lactose tolerance test before and after ingestion of lactosucrose.

FIG. 7 is a graph showing a temporal change in the degree of nausea in a lactose tolerance test before and after ingestion of lactosucrose.

Claims (12)

[Claims] 1. A composition for suppressing abdominal abnormalities caused by lactose intake, comprising lactose sucrose as an active ingredient. 2. The composition according to claim 1, wherein the lactosucrose contains about 0.0001 to 1 g per gram of the composition.
The composition for suppressing abdominal abnormality according to the above. 3. The composition for suppressing abdominal abnormalities according to claim 1, which comprises lactose together with lactosucrose. 4. The mixing ratio of lactose sucrose and lactose is
The composition for suppressing abdominal abnormality according to claim 3, wherein the weight of the solid is in the range of 0.01: 1 to 1: 0.01. 5. The composition for suppressing abdominal abnormality according to claim 1, 2, 3, or 4 as a liquid preparation, a semi-solid preparation, a solid preparation or a powder. 6. As a stabilizer of lactose sucrose, p
Claims 1 and 2, characterized by containing an H buffer.
6. The composition for suppressing abdominal abnormality according to 3, 4, or 5. 7. The composition for suppressing abdominal abnormality according to claim 6, wherein the pH buffer is an organic acid. 8. The composition for suppressing abdominal abnormality according to claim 7, wherein the organic acid is one or more selected from citric acid, tartaric acid, lactic acid, malic acid, carbonic acid and salts thereof. Stuff. 9. The method according to claim 1, which further has an action of inhibiting the generation of putrefactive substances produced by putrefactive bacteria in the intestine.
The composition for suppressing abdominal abnormality according to 3, 4, 5, 6, 7, or 8. 10. The composition for suppressing abdominal abnormalities according to claim 1, wherein the composition comprises a mineral. 11. The composition for suppressing abdominal abnormalities according to claim 10, wherein the mineral is calcium, magnesium, phosphorus or a salt thereof. 12. The method according to claim 1, which further has a mineral absorption promoting action.
The composition for suppressing abdominal abnormality according to 9, 10, or 11.